Yaron Werber, an analyst from TD Cowen, maintained the Buy rating on Ascendis Pharma (ASND – Research Report). The associated price target was raised to $162.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Yaron Werber has given his Buy rating due to a combination of factors that signal potential growth for Ascendis Pharma. One of the primary reasons is the successful launch of Yorvipath, with 80% of patients being new to this treatment, indicating strong market adoption. The stabilization of Skytrofa’s pricing is expected to align with volume growth, with projections showing significant year-over-year increases, further bolstering revenue prospects.
Additionally, upcoming regulatory milestones such as the TransCon CNP NDA filing and potential label extension for Skytrofa provide strong catalysts for future growth. The positive outlook is further supported by revised financial models that show increased revenue estimates for Skytrofa and Yorvipath. These factors, coupled with an anticipated profitability by 2026, have led to an increased price target for Ascendis Pharma’s stock, reinforcing the Buy recommendation.
In another report released on February 11, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $170.00 price target.